IDEAS home Printed from https://ideas.repec.org/r/wly/hlthec/v12y2003i12p1061-1067.html
   My bibliography  Save this item

An empirical comparison of EQ‐5D and SF‐6D in liver transplant patients

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. L. M. Lamers & C. A. M. Bouwmans & A. van Straten & M. C. H. Donker & L. Hakkaart, 2006. "Comparison of EQ‐5D and SF‐6D utilities in mental health patients," Health Economics, John Wiley & Sons, Ltd., vol. 15(11), pages 1229-1236, November.
  2. Richard Grieve & Marina Grishchenko & John Cairns, 2009. "SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 15-23, February.
  3. Yaling Yang & John Brazier & Louise Longworth, 2015. "EQ-5D in skin conditions: an assessment of validity and responsiveness," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 927-939, December.
  4. Susanne Schmitz & Tatjana T. Makovski & Roisin Adams & Marjan Akker & Saverio Stranges & Maurice P. Zeegers, 2020. "Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity," PharmacoEconomics, Springer, vol. 38(1), pages 85-95, January.
  5. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
  6. Brazier, J, 2005. "Current state of the art in preference-based measures of health and avenues for further research," MPRA Paper 29762, University Library of Munich, Germany.
  7. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
  8. Bruno Casal & Eva Rodríguez-Míguez & Berta Rivera, 2020. "Measuring intangible cost-of-morbidity due to substance dependence: implications of using alternative preference-based instruments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1039-1048, September.
  9. Cecilia Quercioli & Gabriele Messina & Emanuela Barbini & Giovanni Carriero & Mara Fanì & Nicola Nante, 2009. "Importance of sociodemographic and morbidity aspects in measuring health-related quality of life: performances of three tools," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(4), pages 389-397, October.
  10. Garry R. Barton & Tracey H. Sach & Anthony J. Avery & Claire Jenkinson & Michael Doherty & David K. Whynes & Kenneth R. Muir, 2008. "A comparison of the performance of the EQ‐5D and SF‐6D for individuals aged ≥ 45 years," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 815-832, July.
  11. Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
  12. Stirling Bryan & Louise Longworth, 2005. "Measuring health-related utility:," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(3), pages 253-260, September.
  13. Richard Huan Xu & Dong Dong & Nan Luo & Eliza Lai-Yi Wong & Yushan Wu & Siyue Yu & Renchi Yang & Junshuai Liu & Huiqin Yuan & Shuyang Zhang, 2021. "Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 547-557, June.
  14. John Brazier & Roberta Ara & Donna Rowen & Helene Chevrou-Severac, 2017. "A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models," PharmacoEconomics, Springer, vol. 35(1), pages 21-31, December.
  15. Nick Kontodimopoulos & Michalis Argiriou & Nikolaos Theakos & Dimitris Niakas, 2011. "The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(4), pages 383-391, August.
  16. Richard Huan Xu & Ming Lu & Shuyang Zhang & Dong Dong, 2023. "EQ-5D and SF-6D health utility scores in patients with spinal and bulbar muscular atrophy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(8), pages 1399-1410, November.
  17. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.
  18. Tsuchiya, Aki & Brazier, John & Roberts, Jennifer, 2006. "Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets," Journal of Health Economics, Elsevier, vol. 25(2), pages 334-346, March.
  19. Janelle Seymour & Paul McNamee & Anthony Scott & Michela Tinelli, 2010. "Shedding new light onto the ceiling and floor? A quantile regression approach to compare EQ‐5D and SF‐6D responses," Health Economics, John Wiley & Sons, Ltd., vol. 19(6), pages 683-696, June.
  20. Fan Yang & Nancy Devlin & Nan Luo, 2019. "Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 99-105, February.
  21. Marra, Carlo A. & Woolcott, John C. & Kopec, Jacek A. & Shojania, Kamran & Offer, Robert & Brazier, John E. & Esdaile, John M. & Anis, Aslam H., 2005. "A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis," Social Science & Medicine, Elsevier, vol. 60(7), pages 1571-1582, April.
  22. Fan Yang & Titus Lau & Evan Lee & A. Vathsala & Kee Chia & Nan Luo, 2015. "Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1019-1026, December.
  23. Carmen Selva-Sevilla & Paula Ferrara & Manuel Gerónimo-Pardo, 2020. "Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 649-662, June.
  24. Silvia Garrido & Ildefonso Méndez & José-María Abellán, 2013. "Analysing the Simultaneous Relationship Between Life Satisfaction and Health-Related Quality of Life," Journal of Happiness Studies, Springer, vol. 14(6), pages 1813-1838, December.
  25. Jacinto Nogueira & Eva Rodríguez-Míguez, 2015. "Using the SF-6D to measure the impact of alcohol dependence on health-related quality of life," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 347-356, May.
  26. Alice Morgan & Sally Hartmanis & Emmanuel Tsochatzis & Philip N. Newsome & Stephen D. Ryder & Rachel Elliott & Lefteris Floros & Richard Hall & Victoria Higgins & George Stanley & Sandrine Cure & Shar, 2021. "Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 505-518, June.
  27. Nick Kontodimopoulos & Evelina Pappa & Zinovia Chadjiapostolou & Eleni Arvanitaki & Angelos Papadopoulos & Dimitris Niakas, 2012. "Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 111-120, February.
  28. Lene Lunde, 2013. "Can EQ-5D and 15D be used interchangeably in economic evaluations? Assessing quality of life in post-stroke patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 539-550, June.
  29. Ilanca Fraser & Johanita Burger & Martie Lubbe & George Dranitsaris & Mark Sonderup & Tienie Stander, 2016. "Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa," PharmacoEconomics, Springer, vol. 34(4), pages 403-417, April.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.